Yesterday's migraine treatment breakthrough, though amidst a complex journey to find a cure, still promises a dramatic impact despite the absence of a 'magic bullet.'
The National Institute for Health and Care Excellence (NICE) has issued guidance recommending GSK's Omjjara (momelotinib) as a treatment option for disease-related splenomegaly.
Patients with a rare and incurable blood cancer, associated with an overproduction of blood cells, will soon have access to a small molecule Novartis treatment.
Organizations or individuals desiring change is often the reason for retirements, but the timing is often crucial and so it proved for two major institutions in the UK.
Highlighting the threat of AMR, the UK government has worked with the pharma industry to develop a new antibiotics payment model based on ‘usefulness’ to the NHS.
